Our website uses cookies to make navigation as functional as possible and to perform statistics on its usage. Should you wish to receive more information, or deny your consent to all or some of the cookies, please click here. By continuing to browse this website, you will be accepting our cookies.
Continuous blood glucose monitoring: the Menarini Diagnostics digital “patch” now available!
Measuring blood sugar several times a day for people with diabetes, will no longer be necessary. Menarini Diagnostics has launched GlucoMen® Day CGM, an innovative digital patch, wearable for  fourteen  days in a row, which m...
Menarini Group Completes a Solid Year of Operating Performance
Menarini Group announced its 2019 results.
Menarini Group Completes Acquisition of Stemline Therapeutics
Menarini Group today announced that is has successfully completed the acquisition of Stemline Therapeutics Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology...
Menarini invests 150 million euros in a new pharmaceutical plant in Italy
Menarini chooses Italy for its new €150 million manufacturing site.
25th EHA Congress: Menarini Ricerche discloses first results from the clinical study on SEL24/MEN1703
Menarini Ricerche announces the completion of the dose escalation part    of the First in Human, phase I/II DIAMOND trial (CLI24-001; NCT03008187) currently ongoing to evaluate SEL24/MEN1703
Menarini Group  and Stemline Therapeutics Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, (Nasdaq: STML) today announced a definitive agreeme...
Page 3 of 6First   Previous   1  2  [3]  4  5  6  Next   Last